August Troendle Sells 21,883 Shares of Medpace (NASDAQ:MEDP) Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 21,883 shares of the company’s stock in a transaction dated Monday, September 21st. The shares were sold at an average price of $623.29, for a total transaction of $13,639,455.07. Following the completion of the transaction, the chief executive officer owned 482,390 shares in the company, valued at approximately $300,668,863.10. This trade represents a 4.34% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Medpace Stock Performance

NASDAQ:MEDP traded down $13.04 during mid-day trading on Wednesday, hitting $617.15. 272,881 shares of the stock were exchanged, compared to its average volume of 333,111. The stock has a market capitalization of $17.22 billion, a price-to-earnings ratio of 36.18, a price-to-earnings-growth ratio of 2.78 and a beta of 1.15. The firm’s 50-day simple moving average is $589.62 and its 200 day simple moving average is $513.16. Medpace Holdings, Inc. has a fifty-two week low of $373.00 and a fifty-two week high of $677.90.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. The firm had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company’s revenue for the quarter was up 17.2% on a year-over-year basis. During the same period in the prior year, the firm posted $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, analysts predict that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of MEDP. Johnson Financial Group Inc. acquired a new stake in Medpace during the 2nd quarter valued at approximately $27,000. Jones Financial Companies Lllp acquired a new position in shares of Medpace in the 2nd quarter worth approximately $30,000. Allied Private Wealth LLC acquired a new position in shares of Medpace in the 2nd quarter worth approximately $31,000. Kilter Group LLC bought a new stake in shares of Medpace in the 2nd quarter valued at $31,000. Finally, Basecamp Wealth Advisors LLC boosted its stake in shares of Medpace by 187.5% in the 1st quarter. Basecamp Wealth Advisors LLC now owns 69 shares of the company’s stock valued at $33,000 after purchasing an additional 45 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

Analyst Ratings Changes

Several research firms recently commented on MEDP. Royal Bank Of Canada upped their price target on shares of Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a research note on Friday, July 24th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $535.00 target price on shares of Medpace in a research report on Thursday, July 23rd. Jefferies Financial Group reaffirmed a “hold” rating on shares of Medpace in a report on Monday, September 14th. BMO Capital Markets lifted their price target on shares of Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a research report on Friday, July 24th. Finally, Mizuho boosted their price target on Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a research note on Friday, July 24th. Three investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $595.20.

Medpace Company Profile

Medpace Holdings, Inc is a global contract research organization (CRO) that provides outsourced clinical development services to pharmaceutical, biotechnology and medical device companies. The company supports sponsors throughout the drug and medical product development process, from early-stage planning and clinical trial design through study execution, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, data management, biostatistics, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.